Cycle Pharmaceuticals launches SAJAZIRTM (icatibant) Injection, a new treatment option in Hereditary Angioedema (HAE)
September 28, 2021 at 07:00 AM EDT
Cycle Pharmaceuticals (Cycle) is pleased to announce the launch of SAJAZIR™ (icatibant) Injection, a new treatment option for patients affected by Hereditary Angioedema (HAE) approved by the US Food and Drug Administration (FDA).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210928005566/en/
SAJAZIR™ is a bradykinin B2 receptor antagonist indicated for treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.
SAJAZIR™ patients will benefit from the newly created Cycle Vita™ support hub for patients with rare diseases (www.cyclevita.life).
Hereditary Angioedema (HAE) is a rare genetic potentially life-threatening disorder that results in recurring attacks of oedema (swelling) in various parts of the body, including the abdomen, extremities (hands/feet), genitals, face, and throat. It is estimated that there are more than 7,000 patients with HAE in the United States.
SAJAZIR™ is supplied in a prefilled syringe delivering 30 mg icatibant. Patients may self-administer SAJAZIR™ subcutaneously upon recognition of symptoms of a HAE attack after training under the guidance of a Healthcare Professional or a Registered Nurse from Cycle Vita™.
“The launch of SAJAZIR™ gives the HAE community an exciting new treatment option. Cycle understands the importance of providing product support to complement the impact of therapeutic products. SAJAZIR™ patients can take advantage of our newly launched product support hub, Cycle Vita™.” said Zac Bohlen, Cycle’s VP of US Sales.
Cycle Vita™, the new product support platform launched by Cycle earlier this month, provides a range of product information and support to Healthcare Providers and rare disease patients across the United States who have been prescribed a Cycle medicine.
“Cycle Vita™ is an essential part of our core mission to better support patients with HAE and their families. We will appropriately guide patients through every stage of their journey by streamlining the enrollment and finance process and provide ongoing treatment support in addition to the expertise of the patient’s healthcare team.” said John Reid, Director of patient hub services.
IMPORTANT SAFETY INFORMATION
The most common side effects of SAJAZIR™ include:
These are not all of the possible side effects of SAJAZIR™. Tell your healthcare provider if you have any side effect that bothers you or that does not go away.
Tell your healthcare provider if you have any other medical conditions, if you are breastfeeding or plan to breastfeed, or if you are pregnant or planning to become pregnant. SAJAZIR™ has not been evaluated in pregnant or nursing women. You and your healthcare provider will decide if SAJAZIR™ is right for you.
If your symptoms continue or come back, you may repeat your SAJAZIR™ injection at least 6 hours apart. Do not use more than 3 doses of SAJAZIR™ in a 24-hour period.
Tiredness, drowsiness, and dizziness have been reported following the use of SAJAZIR™. If this occurs, do not drive a car, use machinery, or do anything that needs you to be alert.
To report SUSPECTED ADVERSE REACTIONS, contact Cycle Pharmaceuticals at 1-800-836-4380, or the FDA at: 1-800-FDA-1088 or www.fda.gov/medwatch.
SAJAZIR™ and Cycle Vita™ are trademarks of Cycle Pharmaceuticals Limited in the United States.
US-SJR-2100017 September 2021
About Cycle Vita™
*Eligibility criteria may apply to ensure compliance with all applicable federal and state requirements, and benefits may be limited to commercially insured patients only.
About Cycle Pharmaceuticals